Connect with us

Headlines

FDA Approves Kala’s Eysuvis for Dry Eye

It’s set to launch this year.

mm

Published

on

WATERTOWN, MA — Kala Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has approved Eysuvis 0.25% for short-term treatment of signs and symptoms of dry eye disease.

“The FDA approval of EYSUVIS as the first prescription therapy specifically developed to address the short-term treatment needs of people living with dry eye disease is a major accomplishment for Kala and an important moment for patients, who have been waiting for an FDA-approved, safe, effective and fast-acting therapy,” said Mark Iwicki, CEO of Kala Pharmaceuticals.

11 Images That Show Why The Novel Eye in North Kingstown Was Named One of America’s Finest Optical Retailers for 2023-24
Photo Gallery

11 Images That Show Why The Novel Eye in North Kingstown Was Named One of America’s Finest Optical Retailers for 2023-24

11 Images That Show Why Respect Eyecare in Calgary Was Named One of (North) America’s Finest Optical Retailers
Photo Gallery

11 Images That Show Why Respect Eyecare in Calgary Was Named One of (North) America’s Finest Optical Retailers

INVISION and MIDO a Match Made in Milan
Photo Gallery

INVISION and MIDO a Match Made in Milan

“As we prepare to launch EYSUVIS, we will leverage our strong foundation of highly experienced ophthalmology marketing, sales and market access professionals with the goal of establishing EYSUVIS as the preferred, first-line prescription therapy for dry eye disease. We’d like to thank the many patients and investigators that were involved in the clinical trials that led to this important milestone.”

Eysuvis (loteprednol etabonate ophthalmic suspension) uses Kala’s Ampplify mucus-penetrating particle drug delivery technology to enhance penetration of loteprednol etabonate  into target tissue on the ocular surface. Loteprednol etabonate  targets the immune responses that drive acute dry eye disease flares, according to a press release from the company.

“Prior to EYSUVIS, there were no FDA-approved ocular corticosteroids for the treatment of dry eye disease,” the release explains.

Advertisement

Kala (NASDAQ: KALA) plans to launch Eysuvis in the U.S. by the end of the year.

“Dry eye disease can significantly decrease quality-of-life among affected patients and drive decreased workplace productivity, contact lens intolerance and discontinuation, and poor cataract and refractory surgery outcomes,” said Kelly Nichols, OD, dean of the University of Alabama at Birmingham School of Optometry. “As the prevalence of dry eye disease increases, there is a tremendous need for new therapies to manage mild-to-moderate dry eye disease patients, many of whom currently go untreated. I am excited by the approval of EYSUVIS and confident that having access to an approved corticosteroid specifically for dry eye disease will meaningfully impact the management of patients across the U.S.”

The FDA granted approval to Eysuvis based on results from four clinical trials, including three Phase 3 trials and one Phase 2 trial, that demonstrated significant improvements in both the signs and symptoms of dry eye disease. The drug is approved for short-term (up to two weeks) treatment, the company explains.

SPONSORED VIDEO

SPONSORED BY VARILUX

The Best Overall Progressive Lens, Now Powered by AI

Engineered with Behavioral Artificial Intelligence and utilizing new XR-motion™ technology, Varilux XR series goes beyond prescription and eye physiology to consider the patient’s visual behavior and design a progressive lens that respects how
their eyes naturally move.

Varilux XR series comes in two versions, Varilux® XR design and Varilux® XR track. The Varilux XR track lens provides an additional level of personalization by incorporating the exclusive Near Vision Behavior Measurement, providing up to 25% more near vision width3 according to the patient’s need, so patients get the highest level of customization.

Discover Varilux XR series and enjoy instantly sharp vision in motion4 and seamless transitions from near to far.

For more information, visit here.

Promoted Headlines

Advertisement

Advertisement

Subscribe

INVISIONMAG.COM
BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Advertisement

Most Popular